Sheet

1	2/2	E	3
	SEP 1	4 1999	FFICE 6
	A Collection	or inversely	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to accepting of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known						
Application Number	09/226,044					
Filing Date	January 5, 1999					
First Named Inventor	Allan S. Hoffman					
Group Art Unit	1615					
Examiner Name						
Attorney Docket Number	UWS 102 (OTT 2219-2744 DL)					

	U.S. PATENT DOCUMENTS									
Examiner Cite No.1			of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
\rack{\alpha\rack{\lambda}{\lambda}}		4,657,543	Langer, et al.	04-14-1997						
4		5,501,584	Yamamoto, et al.	03-26-1996						
		5,521,291	Curiel, et al.	05-28-1996						
5,547,932 C		5,547,932	Curiel, et al.	09-20-1996						
	5,599,908		Raso	02-04-1997						
	,	5,603,931	Raso	02-18-1997						
\Box	/	5,656,609	Wu, et al.	09-12-1997						
W										
			+							

Examiner Initials*	Cite No.1						Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-	Pages, Columns, Lines, Where Relevant Passages or Relevant	Τ°
iiiiiais				Applicant of Cited Document	DD-YYYY	Figures Appear				
		Office.3	Number ⁴	Kind Code ⁵ (if known)						
		WO/	96/40958	A1	Baylor College Medicine	12-19-1996	•			
		₩o	97/04832	A1	Mass. Inst. of Tech.	02-13-1997				
		wo	97/09068	A2	Univ. of Washington	03-13-1997				
\square										
								<u> </u>		
		ļ								
			<u> </u>							

Examine		1	Date Considered	1 -7/	1)
Signature				3-1	V
	V				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Sheet

UWS 102 (OTT 2219-2744 DL)

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Filing Date
First Named Inventor

Group Art Unit

Information unless it contains a valid OMB control number

Complete if Known

Application Number

D9/226,044

SEP 1 4 1999

Filing Date
First Named Inventor

Group Art Unit

1615

Attorney Docket Number

Examiner Name

		OTHER ART NON PATENT LITERATURE DOCUMENTS
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
1,5		ABELEV, "Alpha-fetoprotein in ontogenesis and its association with malignant tumors," Adv. Cancer Res. 14:295-350 (1971).
		ANDERSON, et al., "Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides," <i>Bioconjug Chem.</i> 4(1):10-8 (1993).
	· · · · · ·	BUSCHLE, et al., "Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex," <i>Hum Gene Ther.</i> 6(6):753-61 (1995).
		CHOI, et al. "Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-tapgeted gene carrier," <i>Bioconjug Chem.</i> 9(6):708-18 (1998).
		DONBROW, Ed., Microcapsules and Nanoparticles in Medicine and Pharmacy CRC Press:Boca Raton, 1992.
		GEISOW, "Fluorescein conjugates as indicators of subcellular pH. A critical evaluation," Experimental Cell Research 150:29-35 (1984)
		GOLD, et al., "Specific carcinoembryonic antigens of the human digestive system," J. Exp. Med. 122:467-481 (1965).
		GUY, "Current status and future prospects of transdermal drug delivery," Pharm Res. 13(12):1765-9 (1996).
		HAENSLER, et al., "Polyamidoamine cascade polymers mediate efficient transfection of cells in culture," <i>Bioconjugate Chem.</i> 4: 372-379 (1993).
		HUGHES, et al., "Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides," <i>Pharm Res.</i> 13(3):404-10 (1996).

Signature	Kidi	Date Considered	5-00
	<u> </u>	1	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus	sign (+) inside	this box →

,	617-2
	0 5
	SEP 1 4 1999
/	on of information writes it conta
ollecti	on of information unless it conta

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMME

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	form 1449A/F	PTO	Co	omplete if Known
STATE	MENT B	DISCLOSURE Y APPLICANT ets as necessary)	Application Number	09/226,044
,	•	• •	Filing Date	January 5, 1999
			First Named Inventor	Allan S. Hoffman
·		Group Art Unit	1615	
			Examiner Name	

	A:-		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Ť
(M)		KIRCHEIS, et al., "Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery," <i>Gene Ther.</i> 4(5):409-18 (1997).	
		KOST, et al., "Responsive polymer systems for controlled delivery of therapeutics," TIBTECH 10:127-131 (1992).	
	-	PAWLAK, et al., "Template-assembled melittin: structural and functional characterization of a designed, synthetic channel-forming protein," <i>Protein Science</i> 3:1788-1805 (1994).	
		PERALES, et al., "An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes," <i>Eur J Biochem.</i> 226(2):255-66 (1994).	
		PLANK, et al., "The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems," <i>J. Biol. Chem</i> 269: 12918-12924 (1994).	
		PRAUSNITZ, et al., "Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery," <i>Proc Natl Acad Sci U S A.</i> 90(22):10504-8 (1993).	
		PRAUSNITZ, et al., "Reversible skin permeabilization for transdermal delivery of macromolecules," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 14:455-483 (1997).	
		PRAUSNITZ, et al., "Transdermal delivery of heparin by skin electroporation," Biotechnology (N Y). 13(11):1205-9 (1995).	
		PRESS, et al., "Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes," Cancer Research 48:2249-2257 (1988).	
		ROSS, et al., "Gene therapy in the United States: a five-year status report," Hum Gene Ther. 7(14):1781-90 (1996).	
xaminer's		Date Considered Date Considered	_

*EXAMINER:	Initial if reference consid	fered, whether or not citation is in	conformance with MPEP 609.	Draw line through citation i	f not in conformance and	not considere
Include copy of	of this form with next com	nmunication to applicant.				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box \rightarrow	†	

/	61	P	E	7
	SEP	1 4	1999	€ 68 ⁰
NE.	tion of in	format	tion unit	Ŋ

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pag	oerwork i	Reduction	Act of 1995,	no persons are required to respond to	o a coffection of information unless it contains a va	lid OMB control number	
Substitute for form 1449A/PTO			form 1449	A/PTO	TRADEMAN	omplete if Known	
				N DISCLOSURE BY APPLICANT	Application Number	09/226,044	
		(use a	as many s	heets as necessary)			
					Filing Date	January 5, 1999	
					First Named Inventor	Allan S. Hoffman	
					Group Art Unit	1615	
					Examiner Name		
Sheet		4	of	4	Attorney Docket Number	UWS 102 (OTT 2219-2744 DL)	
_				==	NON PATENT LITERATURE DOCUM		
Examiner's Initials*	Cite No. ¹			item (book, magazine, journal	(in CAPITAL LETTERS), title of the article (l, serial, symposium, catalog, etc.), date, pa publisher, city and/or country where publish	ige(s), volume-issue number(s),	T*
Jan.		THOM	1AS, et al	., "Polyelectrolyte-sensiti	zed phospholipid vesicles," Acc. Cl	nem. Res. 25: 336-342 (1992).	
				., "Membrane solubilizatio Irnal 67:1101-1106 (1994		surface activity and membrane binding,"	
				al., "Influence of endoso 43 (1997).	me-destabilizing peptides on efficac	cy of anti-HIV immunotoxins," Bioconjug	

VINOGRADOV, et al., "Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate

WANG, et al., "Delivery of antisense oligonucleotides using HPMA polymer: synthesis of A thiol polymer and its

WEAVER, et al., "Electroporation: A general phenomenon for manipulating cells and tissues," J Cell Biochem.

oligonucleotides," Bioconjug Chem. 9(6):805-12 (1998).

51(4):426-35 (1993).

conjugation to water-soluble molecules," Bioconjug Chem. 9(6):749-57 (1998).

. 1/1	ı		
		WILDER, et al., "Radioimmunotherapy: recent results and future directions," J. Clin. Oncol. 14:1383-1400 (1996).	
			:
Examiner's Signature		Date Considered 3-W	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.